



# ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.  
**Manufacturer of Condoms**

May 22, 2026

To,  
 The Manager,  
 Listing Compliance Department  
**National Stock Exchange of India Limited**  
 Exchange Plaza, Bandra Kurla Complex,  
 Bandra (East), Mumbai-400051

Subject: Submission of Audited Standalone and Consolidated Financial Results along with Auditors Audited Report thereon for the Half Year and Year ended March 31, 2026, pursuant to Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

SYMBOL: ANONDITA  
 ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024, NSE Circular No. NSE/CML/2025/20 dated April 02, 2025, we wish to inform you that the Board of Directors in its meeting held on Friday, May 22, 2026 has considered and approved the Audited Standalone and Consolidated Financial Results along with the Auditors Audit Report thereon for the Half Year and Year ended March 31, 2026 as duly considered and reviewed by the Audit Committee.


Accordingly, we are hereby submitting the Audited Standalone and Consolidated Financial Results along with the Auditors Audited Report thereon for the Half Year and Year ended March 31, 2026.

Further, the Board Meeting commenced at 01:00 P.M. and concluded at 08:30 P.M. with a vote of thanks.

The said information will also be uploaded on the website of the company <https://anonditamedicare.com/>

Kindly take the aforesaid on your record.

Thanking you,  
 Yours Truly  
 For and on behalf of  
 Anondita Medicare Limited

  
 Bhawna Bisht  
 Company Secretary and Compliance Officer  
 Membership No. A70843



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070

Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA

Tel : 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314

# Jain Chopra & Company

Chartered Accountants

**8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001**

1960, First Floor, Outram Line, Delhi - 110009

Ph. : 011-42171194 Mob : 9810247478

E-mail : jainchopra.company@gmail.com

**Independent Auditor's Report**

**The Board of Directors**

**ANONDITA MEDICARE LIMITED**

## **Opinion**

We have audited the accompanying standalone financial results of **ANONDITA MEDICARE LIMITED** (the "Company") for half year ended 31<sup>st</sup> March 2026 and year to date results for the year from 1<sup>st</sup> April, 2025 to 31<sup>st</sup> March 2026 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulation 2015, as amended (Listing Regulations)

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results for the year ended March 31, 2026.

- a. Financial Results are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard as amended; and
- b. Gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards and the accounting principles generally accepted in India, of the net profit and other financial information for the half year and the year ended 31st March, 2026.

## **Conclusion on Audited Standalone Financial Results for the half year and financial year ended 31 March, 2026**

With respect to the Standalone Financial Results for the half year and financial year ended 31 March, 2026, based on our review conducted as stated in Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the half year and financial year ended 31 March, 2026, prepared in accordance with the recognition and measurement principles laid down in the Accounting Standards and other accounting principles generally accepted in India, has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



## **Basis of Opinion on the Audited Standalone Financial Results for the year ended 31 March, 2026**

We conducted our Audit of the standalone Financial Results in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Results' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone Financial Results.

### **Management's Responsibilities for the Standalone Financial Results**

The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of standalone financial results. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit/loss and other financial information in accordance with the applicable Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.


In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

#### **Audit of the Standalone Financial Results for the year ended 31 March, 2026**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected




to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual standalone annual financial results, including the disclosures, and whether the Annual standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results.
- Materiality is the magnitude of misstatements in Annual Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of reasonably knowledgeable user of Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all



relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other matters**

The annual financial results include the results for the half year ended 31st March, 2026 and the corresponding half year ended in the previous year being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the half year of the relevant financial year which were subject to limited review by us.

**For Jain Chopra & Company**


**Chartered Accountants**

**FRN: 002198N**

*Rajesh Kumar*  
**Rajesh Kumar**

**Partner**

**M.No.501860**



**UDIN:26501860HFECFW2132**

**Date: 22/05/2026**

**Place: Noida**

# ANONDITA MEDICARE LIMITED

(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070

CIN:U22193DL2024PLC428183

Standalone Financial Statement as at March 31, 2026

Amount in Rs. Lakhs unless stated otherwise

Particulars	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
<b>I. EQUITY AND LIABILITIES</b>		
<b>1. Shareholders' funds</b>		
(a) Share Capital	1,608.66	1,329.36
(b) Reserves and surplus	9,494.38	1,430.41
(c) Money received against share warrants		
<b>2. Share application money pending allotment</b>		
<b>3. Non - current liabilities</b>		
(a) Long-term borrowings	2,359.62	1,190.76
(b) Deferred Tax Liability (net)	193.52	8.56
(c) Other Long term liabilities		
(d) Long Term Provision	17.80	9.83
<b>4. Current liabilities</b>		
(a) Short-term borrowings	967.80	1,548.34
(b) Trade payables		
A) Total outstanding dues of micro enterprises and small enterprises	141.23	99.37
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	652.64	253.21
(c) Other current liabilities	193.85	134.74
(d) Short-term Provisions	463.62	320.06
<b>Total</b>	<b>16,293.12</b>	<b>6,324.64</b>
<b>ASSETS</b>		
<b>1) Non Current Assets</b>		
<b>(a) Property, Plant and Equipment and Intangible assets</b>		
(i) Property, Plant and Equipment	3,907.98	1,235.16
(ii) Intangible assets		
(iii) Capital Work in Progress	4,149.50	649.61
(iv) Intangible assets under development		
(b) Non-current Investments	351.58	351.58
(c) Deferred tax assets (net)		
(d) Long-term loans and advances	220.79	37.66
(e) Other non - current assets	0.16	0.24
<b>2) Current Assets</b>		
(a) Current investments		
(b) Inventories	1,349.14	896.28
(c) Trade receivables	3,798.80	1,660.42
(d) Cash and cash equivalents	954.10	35.56
(e) Short-term loans and advances	1,109.75	1,150.00
(f) Other current assets	451.32	308.13
<b>Total</b>	<b>16,293.12</b>	<b>6,324.64</b>

As per our Audit Report of even date attached

For JAIN CHOPRA & COMPANY

Chartered Accountants

FRN: 002198N

*Rajesh Kumar*  
Rajesh Kumar  
(Partner)

M.No.501860

UDIN: 26501860HFECFW2132



For & On behalf of the Board

Anondita Medicare Limited

*Anupam Ghosh*

Anupam Ghosh

Managing Director

DIN: 02675517

D-001 Sector -80, Noida -201305



Place: Noida

Date: 22/05/2026

# ANONDATA MEDICARE LIMITED

(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070

CIN:U22193DL2024PLC428183

## Statement of Standalone Audited Financial Results for the Six Months and Year Ended March 31st, 2026

PARTICULARS	For the half year ended			For the year ended	
	As at March 31, 2026 (Audited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2025 (Audited)	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
I. Revenue from operations	6,404.56	4,765.06	3,554.47	11,169.62	6,051.52
II. Other Income	100.35	75.56	7.73	175.91	36.38
<b>III. Total Income (I +II)</b>	<b>6,504.91</b>	<b>4,840.62</b>	<b>3,562.20</b>	<b>11,345.53</b>	<b>6,087.90</b>
IV. Expenses:					
Cost of Materials Consumed	2,867.91	2,353.22	1,894.00	5,221.13	3,376.69
Purchase of Stock-in-Trade	-				
Change in inventories of finished goods, Work in progress and Stock in Trade	(156.25)	(186.94)	(206.53)	(343.19)	(202.97)
Employee benefit expense	391.93	271.06	259.98	662.99	483.66
Financial costs	166.95	181.32	144.36	348.27	289.46
Depreciation and amortization expense	67.09	40.03	38.83	107.12	74.65
Other expenses	1,048.63	649.21	349.54	1,697.84	605.68
<b>Total Expenses</b>	<b>4,386.25</b>	<b>3,307.91</b>	<b>2,479.98</b>	<b>7,694.16</b>	<b>4,627.17</b>
V. Profit before exceptional and extraordinary items and tax (III - IV)	2,118.66	1,532.71	1,082.22	3,651.37	1,460.73
VI. Exceptional Items					
VII. Profit before extraordinary items and tax (V - VI)	2,118.66	1,532.71	1,082.22	3,651.37	1,460.73
VIII. Extraordinary Items					
IX. Profit before tax (VII - VIII)	2,118.66	1,532.71	1,082.22	3,651.37	1,460.73
X. Tax expense:					
(1) Current tax	375.12	370.65	282.41	745.77	361.15
(2) Income tax for earlier years	38.63			38.63	
(3) Deferred tax Liability / (Assets)	169.47	15.49	(8.73)	184.96	8.57
XI. Profit(Loss) for the year from continuing operations (IX - X)	1,535.44	1,146.57	808.54	2,682.01	1,091.01
XII. Profit/(Loss) from discontinuing operations					
XIII. Tax expense of discounting operations					
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)					
XV. Profit/(Loss) for the year (XI + XIV)	1,535.44	1,146.57	808.54	2,682.01	1,091.01
XVI. Earning per equity share:					
(1) Basic	8.49	8.14	7.18	16.65	9.70
(2) Diluted	8.49	8.14	7.18	16.65	9.70

Notes Forming Part Of The Financial Statement

As per our Audit Report of even date attached

For JAIN CHOPRA & COMPANY

Chartered Accountants

Rajesh Kumar  
(Partner)

M.No.501860

UDIN: 26501860HFECFW-2132



For & On behalf of the Board  
Anondita Medicare Limited

Anugam Ghosh  
Managing Director  
DIN: 02675517

D-001 Sector -80, Noida -201305



Place: Noida

Date: 22/05/2026

**ANONDITA MEDICARE LIMITED**  
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:U22193DL2024PLC428183

**Standalone Statement of Cash Flow for the year ended March 31, 2026**

Particulars	As at March 31, 2026	As at March 31, 2025
<b>Profit before tax</b>	3,651.37	1,460.73
<b>Adjustments for:</b>		
Depreciation & amortization expense	107.12	74.65
Interest expense on borrowings	348.27	289.46
Interest income	(10.65)	(3.95)
Provision for Gratuity	-	-
Preliminary exp written off	0.08	0.08
<b>Operating Profit before working capital changes</b>	<b>4,096.19</b>	<b>1,820.96</b>
<b>Changes in operating assets and liabilities:</b>		
Increase/(decrease) in trade payables	441.29	(148.09)
Increase/(decrease) in other current liabilities	59.10	43.70
Increase/(decrease) in Short Term Borrowings	(580.54)	1,101.92
Increase/(decrease) in Short Term Provisions	(319.05)	0.61
Increase/(decrease) in Long Term Provisions	7.97	4.12
Decrease/(increase) in trade receivables	(2,138.37)	(412.15)
Decrease/(increase) in Inventory	(452.86)	(186.13)
Decrease/(increase) in Short Term loans and advances	(86.76)	(372.53)
Decrease/(increase) in Long Term loans and advances	(183.13)	340.89
Decrease/(increase) in other current assets	(143.20)	(185.18)
Decrease/(increase) in other Non-current assets		
	<b>(3,395.53)</b>	<b>207.16</b>
<b>Cash generated from operations</b>	<b>700.66</b>	<b>2,028.12</b>
Income taxes refunded/ (paid)	(321.79)	(41.70)
<b>Net cash flow from operations (A)</b>	<b>378.86</b>	<b>1,986.42</b>
<b>Cash flow from investing activities</b>		
Purchase of /Advances for property, plant & equipment and Intangible assets	(6,279.83)	(871.59)
Sale of property, plant & equipment	-	-
Investment in Noncurrent Investment	-	(20.18)
(Increase)/Decrease in other advance	-	-
Interest received	10.65	3.95
Purchase of Fixed Assets in acquisition of Business		(1,287.83)
Purchase of Investments in acquisition of Business		(331.40)
Purchase of Advances in acquisition of Business		(101.92)
Purchase of Trade Receivable in acquisition of Business		(1,248.27)
Purchase of Inventories in acquisition of Business		(710.15)
Purchase of Other Assets in acquisition of Business		(112.60)
Purchase of Trade advances in acquisition of Business		(378.55)
Purchase of Trade Payable in acquisition of Business		500.67
Purchase of Other Liabilities in acquisition of Business		90.34
Purchase of Borrowings in acquisition of Business		2,401.29
Purchase of Deferred Tax in acquisition of Business		-
Purchase of Provisions in acquisition of Business		5.70
Purchase of Cash & Cash Equivalents in acquisition of Business		34.78
Less: Cash & Cash Equivalents		(34.76)
(Increase)/Decrease in advances to subsidiary	127.01	(698.90)
<b>Net cash used in investing activities (B)</b>	<b>(6,142.17)</b>	<b>(2,559.43)</b>
<b>Cash flow from financing activities</b>		
Proceeds from issue of capital/equity shares		734.04
Further issue of capital	479.30	142.20
Proceeds from share premium	6,470.55	910.09
Share issue expenses	(1,088.60)	(127.19)
Proceeds/(Repayment) of Long Term Borrowings	1,168.86	(1,210.52)
(Repayment)Receipt of borrowing	-	446.42
Interest paid	(348.27)	(289.48)
<b>Net cash flow from/ (used in) financing activities (C)</b>	<b>6,681.84</b>	<b>606.68</b>
<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	<b>918.53</b>	<b>32.65</b>
Cash and cash equivalents at the beginning of the year	35.65	3.00
<b>Cash and cash equivalents at the closing of the year</b>	<b>954.10</b>	<b>35.65</b>
Cash in hand	21.86	14.29
Balances with banks:		
- On FDR	-	-
- on other than current account	610.85	10.00
- On current accounts	144.90	-
	175.49	11.28
<b>Total</b>	<b>954.10</b>	<b>35.65</b>

As per our Audit Report of even date attached  
For JAIN CHOPRA & COMPANY  
Chartered Accountants  
FRN: 002198N

Rajesh Kumar  
(Partner)  
M.No. 501860  
UDIN: 26501860 HFC



For & On behalf of the board  
Anondita Medicare Limited

Anupam Ghosh  
Managing Director  
DIN: 02675517  
D-001 Sector -80, Noida -201305





Place: Noida  
Date: 22/05/2026

## Notes to Financial Result

1. The above audited financial results which are published in accordance with Regulations 33 of the SEBI (Listing and Disclosure Requirements) Regulations 2015, have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 22<sup>nd</sup> May, 2026.
2. These financial results have been prepared in accordance with the recognition and measurement principle of the Accounting Standards (AS) as prescribed under section 133 of the Companies Act 2013, read with Rule 7 of (Company Accounts) Rule 2014 by the Ministry of Company Affairs as amended.
3. As per MCA notification dated 16<sup>th</sup> February 2015, Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation 2009 are exempted from compulsory requirement of adoption of Ind As
4. The Statutory Auditors of the Company have carried out "Limited Review" of the results for the half year ended on September 30, 2025.
5. Earnings per share (EPS) are not annualised except for the half year ended September 30, 2025
6. The above audited consolidated financial results of the company are posted on Company's website and website of stock exchange viz. [www.nseindia.com](http://www.nseindia.com).
7. The figures for the last half-year of the previous year ended March 31, 2025, represent the balancing figures between the audited full-year figures for March 31, 2026.
8. Provision for tax has been made as per Income Tax Act, 1961. Tax expense includes Provision for Current Tax and Provision for Deferred Tax.
9. The requirement of "AS 17 • Segment Reporting" is not applicable to the Company. The Company currently operates only in one business segment.
10. The figures for the previous year have been regrouped, reclassified, or rearranged, where necessary, to align with the current period's classification and disclosure requirements.

For JAIN CHOPRA & COMPANY  
Chartered Accountants  
Firm's Registration No. 002198N

  
Rajesh Kumar  
Partner  
(M. No-501860  
UDIN:26501860HFECFW2132



For & On behalf of the Board  
Anondita Medicare Limited

  
Anupam Ghosh  
Managing Director  
DIN: 02675517



Place: NOIDA  
Dated:22/05/2026

# Jain Chopra & Company

Chartered Accountants

**8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001**

1960, First Floor, Outram Line, Delhi - 110009

Ph. : 011-42171194 Mob : 9810247478

E-mail : jainchopra.company@gmail.com

## Independent Auditor's Report

### The Board of Directors

### ANONDITA MEDICARE LIMITED

### Report on the Audit of Consolidated Financial Results

#### Opinion

We have audited the accompanying statement of consolidated financial result of **ANONDITA MEDICARE LIMITED** ("hereinafter referred to as the 'Holding Company'") its subsidiaries and associates (Holding Company, its subsidiaries and associates together referred to as "the Group"), for the half year ended March 31, 2026 and for the year ended March 31, 2026 attached herewith, being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 as amended (the "Listing Regulation")

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its profit, and its cash flows for the year ended on that date.

- a. Include the annual financial results of the following entities:
  1. Anondita Medicare Limited (Holding Company)
  2. Anondita Healthcare and Rubber Products India Limited (Subsidiary Company)
  3. Anondita Healthcare (Partnership Firm) (Associates)
- b. Are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- c. Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated net profit/loss and other financial information of the Group for the year ended 31st March, 2026

#### Conclusion on Audited Consolidated Financial Results for the half year and financial year ended 31 March, 2026

With respect to the Consolidated Financial Results for the half year and financial year ended 31st March, 2026, based on our review conducted and procedures performed as stated in Auditor's Responsibilities section below and based on the consideration of the audit conducted of the subsidiary company referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the half year and financial year ended 31st March, 2026, prepared in accordance with the recognition and measurement principles laid down in the Accounting Standards and other accounting principles generally accepted in India, has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



## **Basis for Opinion on the Audited Consolidated Financial Results for the year ended 31 March, 2026**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

### **Management's Responsibilities for the Consolidated Financial Results**

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended 31 March, 2026, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the half year and year ended 31 March, 2026 that give a true and fair view of the consolidated net profit and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other financial information of the Group including its subsidiary and associate in accordance with the recognition and measurement principles laid down accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities**

#### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results for the year ended 31 March, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and



are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual financial results/financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditor such other auditor remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

#### Other Matters

The Statement includes the results for the half year ended 31 March, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the half year of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.

The Consolidated Financial Results include the audited financial results of 01 subsidiary and 01 associate. The consolidated financial results reflect total revenue of ₹36.79 crore and net profit after tax of ₹7.45 crore for the year ended March 31, 2026 and for the period from 01st April, 2025 to 31st March, 2026 respectively, as considered in the Consolidated Financial Results, which have not been audited by us. The financial statements present a true and fair view of the state of affairs of the Group, including its business operations, financial position, and its profit and loss for the period under consideration. They have been prepared in accordance with the applicable accounting standards and relevant statutory requirements. The financial information is complete, consistent, and free from material misstatement, and reflects the underlying transactions and events in a fair and transparent manner.

Our opinion on the Consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done.

For Jain Chopra & Company  
Chartered Accountants

FRN: 002198N

  
Rajesh Kumar

Partner

M.No.501860



UDIN: 265018600JUIWG8370

Date: 22/05/2026

Place: Noida.

**ANONDITA MEDICARE LIMITED**  
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmađa Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:U22193DL2024PLC42B183

Consolidated Financial Statement as at March 31, 2026

Amount in Rs. Lakhs unless stated otherwise

Particulars	As at March 31, 2026	As at March 31, 2025
<b>I. EQUITY AND LIABILITIES</b>		
<b>1. Shareholders' funds</b>		
(a) Share Capital	1,808.66	1,329.36
(b) Reserves and surplus	11,114.92	2,380.36
(c) Minority Interest	203.34	118.16
(d) Money received against share warrants	-	-
<b>2. Share application money pending allotment</b>	-	-
<b>3. Non - current liabilities</b>		
(a) Long-term borrowings	2,387.03	1,190.76
(b) Deferred Tax Liability (net)	193.52	8.56
(c) Other Long term liabilities	-	-
(d) Long Term Provision	17.80	9.83
<b>4. Current liabilities</b>		
(a) Short-term borrowings	973.12	1,548.34
(b) Trade payables	-	-
A) Total outstanding dues of micro enterprises and small enterprises	141.23	123.88
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	661.56	257.65
(c) Other current liabilities	248.79	210.06
(d) Short-term Provisions	733.14	512.17
<b>Total</b>	<b>18,483.12</b>	<b>7,689.13</b>
<b>ASSETS</b>		
<b>1) Non Current Assets</b>		
(a) <b>Property, Plant and Equipment and Intangible assets</b>		
(i) Property, Plant and Equipment	3,909.76	1,237.04
(ii) Intangible assets		
(a) Goodwill	19.18	19.18
(iii) Capital Work In Progress	4,149.50	649.61
(iv) Intangible assets under development	-	-
(b) Non-current Investments	331.40	331.40
(c) Deferred tax assets (net)	0.24	0.22
(d) Long-term loans and advances	220.79	37.67
(e) Other non - current assets	0.16	0.28
<b>2) Current Assets</b>		
(a) Current investments	-	-
(b) Inventories	2,075.01	1,349.86
(c) Trade receivables	5,185.67	2,675.33
(d) Cash and Bank balance	965.19	42.94
(e) Short-term loans and advances	1,114.56	950.60
(f) Other current assets	511.66	395.00
<b>Total</b>	<b>18,483.12</b>	<b>7,689.13</b>

Notes: As attached  
As per our Audit Report of even date attached  
For JAIN CHOPRA & COMPANY  
Chartered Accountants  
FRN: 002198N

Rajesh Kumar  
(Partner)  
M.No.501860




UDIN: 26501860JUIWG8370

Place: NOIDA  
Date: 22/05/2026

For & On behalf of the Board  
Anondita Medicare Limited

Anupam Ghosh  
Managing Director  
DIN: 02675517



D-001 Sector -80, Noida -201305

## ANONDIRA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:U22193DL2024PLC428183

Statement of Consolidated Financial Results for the six months and Year ended March 31,2026  
Amount in Rs. Lakhs unless stated otherwise

PARTICULARS	For the Half Year Ended			For the Year ended	
	As at March 31st, 2026 (Audited)	As at Sept 30th, 2025 (Unaudited)	As at March 31st, 2025 (Audited)	As at March 31st, 2026 (Audited)	As at March 31st, 2025 (Audited)
I. Revenue from operations	8,331.87	5,409.70	4,558.57	13,741.57	7,699.07
II. Other Income	43.46	40.78	3.61	84.24	13.88
<b>III. Total Income (I + II)</b>	<b>8,375.33</b>	<b>5,450.48</b>	<b>4,562.18</b>	<b>13,825.81</b>	<b>7,712.95</b>
<b>IV. Expenses:</b>			1,894.00	5,221.13	3,376.69
Cost of Materials Consumed	2,867.91	2,353.22	743.80	1,384.54	744.86
Purchase of Stock-in-Trade	1,199.61	164.93			
Change in inventories of finished goods, Work in progress and Stock in Trade	(500.33)	(79.18)	(420.57)	(579.51)	(293.20)
Employee benefit expense	484.75	348.10	424.94	832.85	686.80
Financial costs	171.45	182.35	145.78	353.80	291.09
Depreciation and amortization expense	67.21	40.87	39.52	108.09	75.79
Other expenses	1,133.47	702.49	323.68	1,835.95	618.70
<b>Total Expenses</b>	<b>5,424.07</b>	<b>3,712.78</b>	<b>3,151.13</b>	<b>9,136.85</b>	<b>5,500.73</b>
V. Profit before exceptional and extraordinary items and tax (III - IV)	2,951.26	1,737.70	1,411.05	4,688.96	2,212.22
VI. Exceptional Items					
VII. Profit before extraordinary items and tax (V - VI)	2,951.26	1,737.70	1,411.05	4,688.96	2,212.22
VIII. Extraordinary Items					
IX. Profit before tax (VII - VIII)	2,951.26	1,737.70	1,411.05	4,688.96	2,212.22
X. Tax expense					
(1) Current tax	594.87	420.42	372.38	1,015.29	553.25
(2) Income Tax for Earlier years	59.08	-		59.08	
(3) Deferred tax Liability / (Assets)	169.45	15.49	(8.80)	184.94	8.50
XI. Profit/(Loss) for the year from continuing operations (IX - X)	2,127.86	1,301.79	1,047.47	3,429.65	1,650.47
XII. Profit/(Loss) from discontinuing operations					
XIII. Tax expense of discounting operations					
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)					
XV. Profit/(Loss) for the year (XI + XIV)	2,127.86	1,301.79	1,047.47	3,429.65	1,650.47
<b>Profit for the Year attributable to</b>					
a. Owners of the Company	1,894.46	1,159.00	1,018.53	3,344.60	1,588.21
b. Minority Interest	233.40	142.79	28.95	85.05	62.26
XVI. Earning per equity share:					
(1) Basic	11.76	9.12	9.31	21.30	14.67
(2) Diluted	11.76	9.12	9.31	21.30	14.67

Notes: As attached

As per our Audit Report of even date attached

For JAIN CHOPRA & COMPANY

Chartered Accountants

FRN: 002196N

Rajesh Kumar

(Partner)

M.No.501860

UDIN: 265018600JUIWG8370

Place: NOIDA

Date: 22/05/2026

For & On behalf of the Board

Anondita Medicare Limited

Anupam Ghosh

Managing Director

DIN: 02675517

D-001 Sector -80, Noida -201305

**ANONDITA MEDICARE LIMITED**  
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Namada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:U22193DL2024PLC428183

Consolidated Statement of Cash Flow for the year ended March 31, 2026


Particulars	As at March 31, 2026	As at March 31, 2025
<b>Profit before tax</b>	4,688.96	2,212.22
<b>Adjustments for:</b>		
Depreciation & amortization expense	108.09	75.79
Interest expense on borrowings	353.80	320.74
Interest income	(10.65)	(3.95)
Loss on sale of Car	-	0.86
Provision for Gratuity	-	-
Preliminary exp written off	0.12	0.12
<b>Operating Profit before working capital changes</b>	<b>5,140.32</b>	<b>2,806.78</b>
<b>Changes in operating assets and liabilities:</b>		
Increase/(decrease) in trade payables	421.26	(484.82)
Increase/(decrease) in other current liabilities	38.72	(117.09)
Increase/(decrease) in Short Term Provisions	(511.16)	0.61
Increase/(decrease) in Long Term Provisions	7.97	4.12
Decrease/(increase) in trade receivables	(2,510.34)	(1,113.82)
Decrease/(increase) in Inventory	(717.00)	(276.37)
Decrease/(increase) in Short Term loans and advances	(163.95)	(1,456.43)
Decrease/(increase) in Long Term loans and advances	(183.13)	340.89
Decrease/(increase) in other current assets	(116.86)	(199.18)
Decrease/(increase) in other Non-current assets	-	-
	<b>(3,734.27)</b>	<b>(3,302.09)</b>
<b>Cash generated from operations</b>	<b>1,406.05</b>	<b>(896.31)</b>
Income taxes refunded/ (paid)	(342.24)	(44.10)
<b>Net cash flow from operations (A)</b>	<b>1,063.81</b>	<b>(740)</b>
<b>Cash flow from investing activities</b>		
Purchase of /Advances for property, plant & equipment and Intangible assets	(6,280.69)	(673.90)
Sale of property, plant & equipment	-	4.23
Investment in Noncurrent Investment	-	(20.18)
(Increase)/Decrease in other advance	-	-
Interest received	10.65	3.95
Purchase of Fixed Assets in acquisition of Business	-	(1,287.83)
Purchase of Investments in acquisition of Business	-	(331.40)
Purchase of Advances in acquisition of Business	-	(101.92)
Purchase of Trade Receivable in acquisition of Business	-	(1,248.27)
Purchase of Inventories in acquisition of Business	-	(710.15)
Purchase of Other Assets in acquisition of Business	-	(112.60)
Purchase of Trade advances in acquisition of Business	-	(378.55)
Purchase of Trade Payable in acquisition of Business	-	500.67
Purchase of Other Liabilities in acquisition of Business	-	90.34
Purchase of Borrowings in acquisition of Business	-	2,401.29
Purchase of Deferred Tax in acquisition of Business	-	-
Purchase of Provisions in acquisition of Business	-	5.70
Purchase of Cash & Cash Equivalents in acquisition of Business	-	(26.72)
Less: Cash & Cash Equivalents	-	26.72
	<b>(6,270.04)</b>	<b>(1,858.60)</b>
<b>Cash flow from financing activities</b>		
Proceeds from issue of capital/equity shares	-	734.16
Further issue of Capital	479.30	142.20
Share Premium	6,470.55	1,464.36
Share Issue Expense	(1,088.60)	(192.11)
Proceeds/(Repayment) of Long Term Borrowings	1,195.27	(1,210.52)
Increase/(decrease) in Short Term Borrowings	(575.22)	1,530.91
(Repayment)/Receipt of borrowing	-	446.42
Interest paid	(353.80)	(320.74)
<b>Net cash flow from/ (used in) financing activities (C)</b>	<b>6,128.50</b>	<b>2,594.68</b>
Net increase/(decrease) in cash and cash equivalents (A+B+C)	922.27	(4.33)
Cash and cash equivalents at the beginning of the year	42.94	47.27
<b>Cash and cash equivalents at the closing of the year</b>	<b>965.21</b>	<b>42.94</b>
Cash in hand	25.26	18.14
Balances with banks:		
- On FDR	900.11	10.00
- on other than current account	155.64	-
- On current accounts	184.20	14.80
<b>Total</b>	<b>965.21</b>	<b>42.94</b>

Notes: As attached

As per our Audit Report of even date attached

For JAIN CHOPRA & COMPANY  
Chartered Accountants  
FRN: 002198N

Rajesh Kumar  
(Partner)  
M.No.501860




UDIN: 265018600JUIWG8370

Place: NOIDA  
Date: 22/05/2026

For & On behalf of the Board

Anondita Medicare Limited

Anupam Ghosh  
Managing Director  
DIN: 02675517



D-001 Sector -80, Noida -201305

## Notes to Financial Result

1. The above audited financial results which are published in accordance with Regulations 33 of the SEBI (Listing and Disclosure Requirements) Regulations 2015, have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 22<sup>nd</sup> May, 2026.
2. These financial results have been prepared in accordance with the recognition and measurement principle of the Accounting Standards (AS) as prescribed under section 133 of the Companies Act 2013, read with Rule 7 of (Company Accounts) Rule 2014 by the Ministry of Company Affairs as amended.
3. As per MCA notification dated 16<sup>th</sup> February 2015, Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation 2009 are exempted from compulsory requirement of adoption of Ind As
4. The Statutory Auditors of the Company have carried out "Limited Review" of the results for the half year ended on September 30, 2025.
5. Earnings per share (EPS) are not annualised except for the half year ended September 30, 2025
6. The above audited consolidated financial results of the company are posted on Company's website and website of stock exchange viz. [www.nseindia.com](http://www.nseindia.com).
7. The figures for the last half-year of the previous year ended March 31, 2025, represent the balancing figures between the audited full-year figures for March 31, 2026.
8. Provision for tax has been made as per Income Tax Act, 1961. Tax expense includes Provision for Current Tax and Provision for Deferred Tax.
9. The requirement of "AS 17 • Segment Reporting" is not applicable to the Company. The Company currently operates only in one business segment.
10. The figures for the previous year have been regrouped, reclassified, or rearranged, where necessary, to align with the current period's classification and disclosure requirements.

Notes: As attached  
As per our Audit Report of even date attached  
For JAIN CHOPRA & COMPANY  
Chartered Accountants  
FRN: 002198N


  
Rajesh Kumar  
(Partner)  
M.No.501860



UDIN: 265018600JUIWG8370

Place: NOIDA  
Date: 22/05/2026

For & On behalf of the Board  
Anondita Medicare Limited

  
Anupam Ghosh  
Managing Director  
DIN: 02675517



D-001 Sector -80, Noida -201305